News | January 11, 2026
PAI Pharma acquires Nivagen to boost US injectable drug production
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
The supplements are made using only vegetarian-sourced ingredients
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
Subscribe To Our Newsletter & Stay Updated
